Prediction of clinical responses in a simulated phase III trial of Crohn's patients administered the antisense phosphorothioate oligonucleotide ISIS 2302: Comparison of proposed dosing regimens

Antisense and Nucleic Acid Drug Development

Volumn 13, Issue 1, 2003, Pages 57-66

  Yu, Rosie Z ^a   Su, John Q ^a   Grundy, John S ^a   Geary, Richard S ^a   Sewell, K Lea ^a   Dorr, Andrew ^a   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; HUMAN; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037301406     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729003764097340     Document Type: Article

References (20)

1. AARONS, L., KARLSSON, M.O., MENTRE, F., ROMBOUT, F., STEIMER, J.L., and VAN PEER, A. (2001). Role of modeling and simulation in phase I drug development. Eur. J. Pharm. Sci. 13, 115-122.
2. BEAL, S.L., and SHEINER, L.B. (1988-1998). NONMEM Users Guides. Part I-VIII. NONMEM Project Group C255, University of California at San Francisco.
3. BRAUNWALD, E., FAUCI, A.S., KASPER, D.L., HAUSER, S.L., LONGO, D.L., and JAMESON, J.L., eds. (2001). Harrison's Principles of Internal Medicine. (McGraw Hill Professional, New York).
4. GEARY, R.S., YU, R.Z., LEEDS, J.M., TEMPLIN, M.V., WATANABE, T.A., HENRY, S.P., and LEVIN, A.A. (2001a). Pharmacokinetic properties in animals. In: Antisense Drug Technology. S.T. Crooke, ed. (Marcel Dekker, New York), pp. 119-154.
5. GEARY, R.S., YU, R.Z., and LEVIN, A.A. (2001b). Pharmacokinetics of phosphorothioate antisense oligonucleotides. Curr. Opin. Invest. Drugs 2, 562-573.
6. GIESCHKE, R., REIGNER, B.G., STEIMER, J.L., and HOFFMANN-LA ROCHE, F. (1997). Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modeling. Int. J. Clin. Pharmacol. Ther. Toxicol. 35, 469-474.
7. GLOVER, J.M., LEEDS, J.M., MANT, T.G., AMIN, D., KISNER, D.L., ZUCKERMAN, J.E., GEARY, R.S., LEVIN, A.A., and SHANAHAN, W.R., JR. (1997). Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. 282, 1173-1180.
8. HARRISON, G.G. (1985). Height-weight tables. Ann. Intern. Med. 103, 489-494.
9. HENRY, S.P., GICLAS, P.C., LEEDS, J., PANGBURN, M., AULETTA, C., LEVIN, A.A., and KORNBRUST, D.J. (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J. Pharmacol. Exp. Ther. 281, 810-816.
10. HOLFORD, N.H.G., KIMKO, H.C., MONTELEONE, J.P.R., and PECK, C.C. (2000). Simulation of clinical trials. Annu. Rev. Pharmacol. Toxicol. 40, 209-234.
11. KHOSLA, T., and LOWE, C.R. (1967). Indices of obesity derived from body weight and height. Br. J. Prev. Soc. Med. 21, 122-128.
12. KIMKO, H.C., REELE, S.S.B., HOLFORD, N.H.G., and PECK, C.C. (2000). Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin. Pharmacol. Ther. 68, 568-577.
13. LEE, J., KOLONEL, L.N., and HINDS, M.W. (1981). Relative merits of the weight-corrected-for-height indices. Am. J. Clin. Nutr. 34, 2521-2529.
14. MEIBOHM, B., and DERENDORF, H. (2002). Pharmacokinetic/pharmacodynamic studies in drug product development. J. Pharm. Sci. 91, 18-31.
15. MONTGOMERY, M.J., BERINGER, P.M., AMINIMANIZANI, A., LOUIE, S.G., SHAPIRO, B.J., JELLIFFE, R., and GILL, M.A. (2001). Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 45, 3468-3473.
16. SEWELL, K.L., GEARY, R.S., BAKER, B.F., MANT, T.G.K., YU, R.Z., TAMI, J.A., DORR, F.A., and GLOVER, J.M. (2003). Phase I trial of ISIS 104838, a 2′-methoxyethyl modified tumor necrosis factor-alpha antisense oligonucleotide. J. Pharmacol. Exp. Ther. In press.
17. VEYRAT-FOLLET, C., BRUNO, R., OLIVARES, R., RHODES, G.R., and CHAIKIN, P. (2000). Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin. Pharmacol. Ther. 68, 677-687.
18. YACYSHYN, B.R., BOWEN-YACYSHYN, M.B., JEWELL, L., ROTHLEIN, R.A., MAINOLFI, E., TAMI, J.A., BENNETT, C.F., KISNER, D.L., and SHANAHAN, W.R. (1998). A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of steroid-dependent Crohn's disease. Gastroenterology 114, 1133-1142.
19. YACYSHYN, B.R., CHEVY, W.Y., GOFF, J., SALZBERG, B., BAERG, R., BUCHMAN, A.L., TAMI, J., YU, R., GIBIANSKY, E., SHANAHAN, W.R., and ISIS 2302-CS9 INVESTIGATORS. (2002). Double-blind, placebo-controlled trial of the remission-inducing and steroid-sparing properties of an ICAM-1 antisense oligodeoxynucleotide alicaforsen (ISIS 2302) in active steroid-dependent Crohn's disease. Gut 51, 30-36.
20. YU, R.Z., SCHOENFELD, S.L., GEARY, R.S., WATANABE, T.A., and LEVIN, A.A. (2001). Pharmacokinetic properties in humans. In: Antisense Drug Technology. S.T. Crooke, ed. (Marcel Dekker, New York), pp. 183-200.